10/01/2026
Rezolute is a late-stage rare disease company focused on substantially improving the quality of life for individuals living with hyperinsulinism (HI) and is now enrolling participants in the upLIFT study, a phase 3 clinical trial that is testing whether or not a new therapy, called ersodetug, can safely reduce hypoglycaemia in adults with tumour HI.
📲 https://www.amend.org.uk/patients/research-opportunities/